

## REMARKS

Applicants have amended claims 41 and 42 to more distinctly recite the claimed invention by reciting antivenom instead of antivenin, as pending claim 40 already recites. As Applicants showed in the Amendment of May 4, 1998, with regard to claim 40, the application supports reciting antivenom at, *inter alia*, page 4, lines 19-22. Upon entry of this Amendment, claims 40-42 and 45-47 will be pending, and none of the claims will recite antivenin.


The Examiner rejected claims 40-42 under 35 U.S.C. § 112, first paragraph, as allegedly not being supported by a written description in Paper No. 33. However, the Examiner did not maintain the rejection in Paper No. 37 upon entry of the Amendment of May 4, 1998.

This Amendment also eliminates any possible indefiniteness by having claims 41 and 42 recite antivenom, as claim 40, from which they depend, does. Accordingly, Applicants respectfully request entry of this Amendment to reduce the issues for appeal.

If there are any fees due in connection with the filing of this Response, please charge the fees to our deposit account no. 06-0916.

Respectfully submitted,

FINNEGAN, HENDERSON, FARABOW,  
GARRETT & DUNNER, L.L.P.

By:   
Michael T. Siekman  
Reg. No. 36,276

Date: August 5, 1998